Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of RIN 150 vs Individual Rifampicin and Isoniazid
NCT02014272Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2012
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rifampicin and isoniazid in Tuberculosis (TB) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Last Quantifiable Concentration at Day 1 and Maximum Observed Plasma Concentration at Day 1. Started Sep 2012; status: completed.
02
Drugs
rifampicinisoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02014272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014272.